Matt Gline, Roivant CEO (courtesy Roivant)

Up­dat­ed: Roivant’s FcRn an­ti­body for au­toim­mune dis­ease shows ear­ly po­ten­tial in study with healthy sub­jects

Roivant Sci­ences’ Im­muno­vant has un­veiled bio­mark­er re­sults for its au­toim­mune dis­ease an­ti­body drug from a Phase I healthy sub­ject tri­al.

The sub­cu­ta­neous drug, dubbed IMVT-1402, tar­gets the neona­tal frag­ment crys­tal­liz­able re­cep­tor (FcRn) for im­munoglob­u­lin G (IgG)-me­di­at­ed au­toim­mune dis­eases.

Im­muno­vant’s stock price $IMVT soared by 87% to about $38.00 on Tues­day in re­sponse to the da­ta, while Roivant $ROIV — which owns a con­trol­ling share of Im­muno­vant — went up by 23% to $12.60.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.